These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21497638)

  • 1. Natural and vaccine-induced immunity to Neisseria meningitidis serogroup C in asplenic patients with β-thalassemia.
    Spoulou V; Tzanakaki G; Lekka S; Chouliaras G; Ladis V; Theodoridou M
    Vaccine; 2011 Jun; 29(27):4435-8. PubMed ID: 21497638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
    de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ
    Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
    Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
    Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.
    Pace D; Snape M; Westcar S; Hamaluba M; Yu LM; Begg N; Wysocki J; Czajka H; Maechler G; Boutriau D; Pollard AJ
    Pediatr Infect Dis J; 2007 Nov; 26(11):1057-9. PubMed ID: 17984816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
    Stoof SP; van der Klis FR; van Rooijen DM; Bogaert D; Trzciński K; Sanders EA; Berbers GA
    Vaccine; 2015 Jul; 33(32):3933-9. PubMed ID: 26100925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis.
    Bettinger JA; Scheifele DW; Halperin SA; Kellner JD; Vanderkooi OG; Schryvers A; De Serres G; Alcantara J
    Vaccine; 2012 Jun; 30(27):4023-7. PubMed ID: 22537988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and preliminary immunogenicity of MenC/P64k, a meningococcal serogroup C conjugate vaccine with a new recombinant carrier.
    Pérez AE; Dickinson FO; Banderas F; Serrano T; Llanes R; Guzmán D; Díaz P; Alvarez A; Guirola M; Caballero E; Canaan-Haden L; Guillén G
    FEMS Immunol Med Microbiol; 2006 Apr; 46(3):386-92. PubMed ID: 16553812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.
    Balmer P; Falconer M; McDonald P; Andrews N; Fuller E; Riley C; Kaczmarski E; Borrow R
    Infect Immun; 2004 Jan; 72(1):332-7. PubMed ID: 14688112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody.
    Perrett KP; Jin C; Clutterbuck E; John TM; Winter AP; Kibwana E; Yu LM; Curtis N; Pollard AJ
    J Immunol; 2012 Sep; 189(5):2673-81. PubMed ID: 22855707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
    Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY
    Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of steroid-treated former preterm infants to a single dose of meningococcal C conjugate vaccine.
    Clarke P; Robinson MJ; Ahmad I; Bedford-Russell AR; Connell JE; Powell PJ; Heath PT
    Vaccine; 2006 Apr; 24(16):3273-8. PubMed ID: 16472548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.
    Auckland C; Gray S; Borrow R; Andrews N; Goldblatt D; Ramsay M; Miller E
    J Infect Dis; 2006 Dec; 194(12):1745-52. PubMed ID: 17109348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.
    Stoof SP; van Ravenhorst MB; van Rooijen DM; de Voer RM; van der Klis FRM; Boland GJ; Sanders EAM; Berbers GAM; Teunis PF
    Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27881489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine.
    Blanchard-Rohner G; Watt H; Kelly DF; Yu LM; Snape MD; Pollard AJ
    Vaccine; 2012 Jun; 30(28):4153-9. PubMed ID: 22554466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of conjugate meningococcus C vaccine in pediatric solid organ transplant recipients.
    Zlamy M; Elias J; Vogel U; Frosch M; Jeller V; Cortina G; Jungraithmayr T; Prelog M
    Vaccine; 2011 Aug; 29(37):6163-6. PubMed ID: 21718742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
    van Ravenhorst MB; den Hartog G; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    PLoS One; 2018; 13(4):e0191261. PubMed ID: 29672552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
    Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
    Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults.
    de Voer RM; van der Klis FR; Engels CW; Schepp RM; van de Kassteele J; Sanders EA; Rijkers GT; Berbers GA
    Vaccine; 2009 Nov; 27(50):6974-82. PubMed ID: 19800445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.